SALT LAKE CITY - Recursion (NASDAQ:RXRX) will present new clinical data from its ongoing TUPELO Phase 1b/2 trial of REC-4881 in Familial Adenomatous Polyposis (FAP) during a company webinar scheduled ...

Getting in on the ground floor would be great, but only if there's massive upside ahead for the company. Several stocks on the market offer investors the opportunity to capitalize on the rapidly ...

Recursion Pharmaceuticals (RXRX) is drawing renewed attention after the appointment of Najat Khan as CEO and news of a narrowing net loss, both viewed as signals of improving execution. Investors also ...

Leading tech companies are in a race to release and improve artificial intelligence (AI) products, leaving users in the United States to puzzle out how much of their personal data could be extracted ...

The Center for American Progress’ data dashboard allows users to explore national- and state-level data trends on a range of child care and early learning topics. Read more and explore additional ...